Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

UCB Wins Two Key US Approvals: Bimzelx In Psoriasis, Zilbrysq In gMG

Launches To Follow In A Month, Late 2023

19 Oct 2023

• By Mandy Jackson

Night speedy motion blur international race track with starting finishing line and confetti — Bimzelx crossed the US finish line after a lengthy delay • Source: Shutterstock

Related Content

UCB’s Rystiggo Becomes Second FcRn Inhibitor Treatment For gMG

28 Jun 2023

UCB Awaits Two Regulatory Verdicts For Bimzelx

13 Oct 2023

UCB Frustrated By FDA Failure To Inspect Facility For Psoriasis Drug

18 Oct 2021

UCB Makes Another Push To Get Bimzelx Over Finishing Line In US

23 Nov 2022

Cimzia Keeps Raking In The Cash As UCB Waits For New Products Impact

10 Jan 2023

Valeant Gives Siliq Competitive Price In Crowded Psoriasis Market

21 Apr 2017

Related Companies

UCB S.A.

Zogenix, Inc.

Novartis AG

Eli Lilly and Company

Bausch Health Companies Inc.

Valeant

argenx N.V.

AstraZeneca PLC

Alexion Pharmaceuticals Inc.

Additional Topics

Approvals Launches Rare Diseases Companies Strategy Commercial Dermatology BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.